The market for real-time PCR (qPCR) is rapidly growing as a result of a number of factors, the most significant of which are the rising incidence of particular diseases and the technological advancements that have resulted in the creation of more sophisticated qPCR equipment. The real-time PCR (qPCR) market is anticipated to rise as a result of an increase in the frequency of genetic illnesses including cancer and syndromes as well as infectious diseases like HIV, malaria, and hepatitis.
The value of the Real-time PCR (QPCR) Instrument and Regent market is projected to grow to USD 10,880.28 Million with an estimated CAGR of 8.71 % by 2030
.jpg "The Global Real Time Pcr Qpcr Instrument And Regent Market 2020-2030 (USD Million)")
Covid-19 Impact and Market Status
The healthcare sector has been severely impacted by the COVID-19 outbreak. It was felt most acutely in the diagnostics sector, where demand has increased at an exponential rate. Digital PCR and real-time PCR have garnered a lot of attention because of their potential applications in disease diagnosis and new drug discovery. As a result, commercial suppliers are placing a premium on developing droplet digital PCR kits for the detection of COVID-19. More than that, numerous industry companies have released cutting-edge tools and brand-new tests specifically for COVID-19 analysis.
North America will dominate the Real-time PCR (QPCR) Instrument and Reagent Market
In the market for real-time PCR (qPCR), North America continues to be the most lucrative area, holding a considerable market share that is close to 57% of the total market. The dominance of North America in this market arena can be attributed, in part, to the region's increased adoption of novel and creative genomic analysis tools as well as the availability of grants for research and development.
Throughout the interest period, Asia-Pacific will experience steady growth.
In Asia Pacific, it is projected that the high prevalence of chronic and infectious diseases, as well as growing patient awareness of early diagnosis of these diseases, would increase demand for PCR products, which will, in turn, fuel the market's expansion over the ensuing years.
The Real-time PCR (QPCR) instruments and reagents industry will be dominated by the hospital sector.
In 2021, the healthcare sector accounted for more than 95 percent of total market revenue thanks to the widespread use of polymerase chain reaction (PCR) testing in clinical diagnostics and research activities pertaining to the study of diseases and the creation of new drugs. The demand for tests is rising as PCR becomes more widely used in areas such as the diagnosis of SARS-CoV-2 infections and the research and development of new drugs. Increasing applications for illness diagnosis, monitoring, and treatment, as well as the high precision of testing methodologies, are also driving the market. qPCR and dPCR reagents for diagnostics are also being increasingly commercialized.
In the near future, the use of clinical diagnostic tests will rise due to the rising prevalence of diseases of interest in all parts of the world and the effectiveness of real-time PCR (qPCR) analysis that has been shown in the estimation and detection of bacteria that are pathogenic to disease. As a result, it is anticipated that this will act as a catalyst for the real-time PCR market to grow (qPCR).
The number of real-time PCR (qPCR) products available in the biotechnology and pharmaceutical industries will rise as real-time polymerase chain reaction (qPCR) methods gain popularity in drug development and other academic disciplines.
As more biotechnology and pharmaceutical businesses concentrate on integrating cutting-edge techniques for diagnosing various illnesses, the real-time PCR (qPCR) market is anticipated to expand rapidly. The growth of biotechnology and pharmaceutical companies is anticipated to further accelerate this growth.
Real-time PCR, also referred to as quantitative PCR, is a proven technology that has become the go-to tool for quickly and accurately quantifying nucleic acid in a variety of biological samples. The market is incredibly cutthroat. Each of these businesses has high-end clients and important patents and technological assets.
These businesses have thus established monopolies in their respective industries. Real-time PCR (QPCR) Instruments accounted for more than 50% of the value share by product in 2019. This was attributed to the product's higher product efficiency.
Research currently accounts for more than 55% of the market value due to the growing use of real-time PCR (qPCR) techniques in drug discovery and other research activities. This results from the fact that the main end user is research. However, in the upcoming years, hospitals and diagnostic centres will be the main forces behind expansion.
One of the main factors influencing the growth of this industry is the availability of real-time PCR (qPCR) products at affordable prices, and this trend will continue. This effort is also driving the market for real-time PCR instrument and reagent.
Real-time PCR (QPCR) Instrument and Reagent market leaders include Thermofisher Scientific, Sigma-Aldrich, F. Hoffmann-La Roche, Vela Diagnostics, Quantabio, BIOTECON Diagnostics, Bio-Rad Laboratories, Shanghai Fosun Long March Medical Science, Agilent Technologies, and Roche Sino Biological. Other market leaders include F. Hoffmann-La Roche, Shanghai Fosun Long March Medical Science, Bio-Rad Laboratories These companies are putting a significant amount of money into research and development in an effort to increase demand for real-time polymerase chain reaction (QPCR) instruments and reagents.
Latest Innovations in The Global Real-time PCR (QPCR) Instrument and Reagent Market: A Snapshot
- QIAGEN N.V. announced in January 2019 that it would be acquiring the U.S. digital polymerase chain reaction (dPCR), one of the fastest-growing molecular diagnostic applications, and has announced the development of a range of next-generation devices for release in 2020.
- To better serve its customers' needs for quantitative polymerase chain reaction (qPCR) products, Danaher Corporation bought Cepheid Inc. in 2016.
Real-time PCR (QPCR) Instrument and Reagent Market Scope
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2030 |
| Study Period | 2018-2030 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2030 | USD 10,880.28 Million |
| Growth Rate | CAGR of 8.71 % during 2020-2030 |
| Segment Covered | By Technology, By Application, By End User, By Products & Services, Region. |
| Regions Covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
| Key Players Profiled | Roche Ltd, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, Qiagen N.V, Takara Bio, Inc, Agilent Technologies, Inc., BioMerieux SA, Danaher Corporation and Merck KGaA. |
Key segments of The Global PCR (QPCR) Instrument and Reagent Market
Type Overview (USD Million)
- Instruments
- Reagents and Consumables
End-User Overview, (USD Million)
- Hospitals
- Diagnostics
- Pharmacies
- Research Institutes
- Biotechnology Industries
Application Overview, (USD Million)
- Research
- Forensic
- Clinical
Regional Overview, (USD Million)
- North America
- United States of America
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- the Netherlands
- Poland
- Russia
- The United Kingdom
- Rest of Europe
- Asia-Pacific
- China
- India
- Indonesia
- South Korea
- Rest of Asia-Pacific
- South America
- Argentina
- Brazil
- Peru
- Uruguay
- Rest of South America
Frequently Asked Questions (FAQ) :
The market value of real-time pcr instrument and reagent market in 2030 was USD 10,880.28 Million.
The real-time pcr instrument and reagent market is growing at a CAGR of 8.71 % over the forecast period.
The top companies that hold the market share in real-time pcr instrument and reagent market are Roche Ltd, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, Qiagen N.V, Takara Bio, Inc, Agilent Technologies, Inc., BioMerieux SA, Danaher Corporation and Merck KGaA.